Mucopolysaccharidosis type VII (MPS VII) is a member of a group of inherited metabolic disorders collectively termed mucopolysaccharidoses (MPSs). The MPSs are caused by a deficiency of lysosomal enzymes required for the degradation of mucopolysaccharides also called glycosaminoglycans (GAGs) within the lysosome. When functioning normally, the lysosomal enzymes break down these GAGs, however when the enzyme is deficient, the GAG build up in the lysosomes causing damage to the bodys tissues. The MPSs share a chronic progressive course with multisystem involvement, several physical features, laboratory findings, and radiographic abnormalities; these include facial coarsening, hepatomegaly, excretion of urinary GAG fragments, and leukocyte inclusion bodies.
Mucopolysaccharidosis type VII (MPS VII) is an autosomal recessive that occurs when certain mucopolysaccharides, specifically dermatan, heparan, and chondroitin sulfates accumulate in lysosomes due to a deficiency of the enzyme beta-glucuronidase. Unlike other lysosomal storage disorders in which patients begin life with a period of normal development, patients with MPS VII have a high incidence of hydrops fetalis . Clinical features of MPS VII vary widely between patients and include short stature, course facial features, hepatosplenomegaly, respiratory difficulties, hearing loss, and mental retardation.
Mutations in the GUSB gene cause deficiency of beta-glucuronidase leading to MPS VII. A pseudodeficiency allele, a mutation that reduce enzyme activity but does not cause disease, has been described  and will be detected by this sequencing analysis. Diagnostic sequencing analysis of the GUSB gene coding region is available for MPS type VII patients and their at-risk relatives on a clinical basis.
For patients with mutations not identified by full gene sequencing, a separate deletion/duplication assay is available using a targeted CGH array (NC).
For questions about testing for MPS VII, call EGL Genetics at (470) 378-2200 or (855) 831-7447. For further clinical information about lysosomal storage diseases, including management and treatment, call the Emory Lysosomal Storage Disease Center at (404) 778-8565 or (800) 200-1524.
1. Muenzer, J., The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr, 2004. 144(5 Suppl): p. S27-34.
2). Vervoort, R., M.R. Islam, W. Sly, A. Chabas, R. Wevers, J. de Jong, I. Liebaers, and W. Lissens, A pseudodeficiency allele (D152N) of the human beta-glucuronidase gene. Am J Hum Genet, 1995. 57(4): p. 798-804.
3). Vervoort, R., N.R. Buist, W.J. Kleijer, R. Wevers, J.P. Fryns, I. Liebaers, and W. Lissens, Molecular analysis of the beta-glucuronidase gene: novel mutations in mucopolysaccharidosis type VII and heterogeneity of the polyadenylation region. Hum Genet, 1997. 99(4): p. 462-8.
4). Yamada, S., S. Tomatsu, W.S. Sly, R. Islam, D.A. Wenger, S. Fukuda, K. Sukegawa, and T. Orii, Four novel mutations in mucopolysaccharidosis type VII including a unique base substitution in exon 10 of the beta-glucuronidase gene that creates a novel 5'-splice site. Hum Mol Genet, 1995. 4(4): p. 651-5.
5). Vervoort, R., M.R. Islam, W.S. Sly, M.T. Zabot, W.J. Kleijer, A. Chabas, A. Fensom, E.P. Young, I. Liebaers, and W. Lissens, Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII. Am J Hum Genet, 1996. 58(3): p. 457-71.
- Confirmation of a clinical diagnosis of MPS VII
- Prenatal testing for known familial mutations.
- Assessment of carrier status in high risk family members known mutation analysis.
Prevalence: The estimated prevalence of all lysosomal storage disorders is 2-5 per 100,000. The prevalence of MPS VII is not specifically known, but is likely to be rare and may vary by ethnicity.
Targeted CGH Array:
Detection is limited to duplications and deletions. Array CGH will not detect point mutations or intronic mutations. Results of molecular analysis must be interpreted in the context of the patient's clinical and/or biochemical phenotype.
Infants and Young Children (<2 years of age): 2-3 ml
Children > 2 years of age to 10 years old: 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood
Isolation using the Perkin Elmer™Chemagen™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.
Orangene™ Saliva Collection Kit used according to manufacturer instructions. Please contact EGL for a Saliva Collection Kit for patients that cannot provide a blood sample.
- Mucopolysaccharide Screen (Urine GAG) (GA)
- Lysosomal Enzyme Screening Panel (LS)
- Deletion/Duplication Assay is available separately for individuals where mutations are not identified by sequence analysis. Refer to the test requisition or contact the laboratory for more information.
- Known Mutation Analysis (KM) is available to test family members.
- Prenatal testing is available for known familial mutations only. Please call the Laboratory Genetic Counselor for specific requirements for prenatal testing before collecting a fetal sample.